Trials / Completed
CompletedNCT00496327
Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)
Evaluation of Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX (V210)in Healthy Indian Children
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 12 Years – 12 Years
- Healthy volunteers
- Accepted
Summary
To observe the safety and tolerability of the administration of VARIVAX in varicella history negative Indian children 12 months to 12 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Varicella Virus Vaccine Live (Oka-Merck) | VARIVAX(TM) (Refrigerated) \[Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.\] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose. |
Timeline
- Start date
- 2005-06-22
- Primary completion
- 2005-10-06
- Completion
- 2005-10-06
- First posted
- 2007-07-04
- Last updated
- 2019-01-18
Source: ClinicalTrials.gov record NCT00496327. Inclusion in this directory is not an endorsement.